ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

N-Methyl-3,4-methylenedioxyamphetamine

Also written as “Midomafetamine HCl”, “Midomafetamine” and “midomafetamine HCl”.

Its studies are mostly in Stress Disorders, Post-Traumatic · Autism Spectrum Disorder · Autistic Disorder · Anxiety Disorders · Binge-Eating Disorder, led by 4 companies.

Drug pageN-Methyl-3,4-methylenedioxyamphetamine: every studyAll 91 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 3, since May 14, 201829 company-led studies, 2 open or runningNext primary completion: Dec 2028 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Resilient Pharmaceuticals262 open or runningphase 3since May 14, 2018Aug 24, 2004Dec 2028phase 1 · NCT03606538
Definium Therapeutics USits history only10 open or runningphase 2since Dec 22, 2025Dec 22, 2025none ahead
MAPS Europeits history only10 open or runningphase 2since Jul 19, 2019Jul 19, 2019none ahead
Remedyits history only10 open or runningphase 2since Sep 19, 2021Sep 19, 2021none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Resilient Pharmaceuticals only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 12 studies since Aug 24, 2004.

  1. Jun 5, 2017Phase 1 study in Startle ResponseNCT03181763 · 34 enrolled · United States
  2. Sep 11, 2017Phase 2 study in Stress Disorders, Post-TraumaticNCT03282123 · 38 enrolled · United States
  3. Mar 23, 2018Phase 2 study in Stress Disorders, Post-TraumaticNCT03485287 · 4 enrolled · Canada
  4. May 14, 2018Phase 3 study in Stress Disorders, Post-TraumaticNCT03537014 · 100 enrolled · United States, Canada, Israel
  5. Jul 20, 2018Phase 1 study in PharmacokineticsNCT03606538 · 16 planned · United States
  6. Jul 30, 2019Phase 1 study in Psychological Effects of Study DrugNCT04073433
  7. Aug 30, 2019Phase 3 study in Stress Disorders, Post-TraumaticNCT04077437 · 121 enrolled · United States, Israel
  8. Jun 26, 2020Phase 2 study in Binge-Eating DisorderNCT04454684
  9. Jan 14, 2021Phase 3 study in Stress Disorders, Post-TraumaticNCT04714359 · 87 enrolled · United States, Canada, Israel
  10. Mar 2, 2021Phase 2 study in Stress Disorders, Post-TraumaticNCT04784143 · 26 enrolled · United States
  11. Jul 9, 2021Phase 2 study in Stress Disorders, Post-TraumaticNCT04968938
  12. Nov 24, 2021Phase 1 study in PharmacokineticsNCT05147402 · 14 enrolled · United States
  13. Dec 13, 2021Phase 2 study in Stress Disorders, Post-TraumaticNCT05173831
  14. Apr 30, 2026Phase 1 study in Healthy VolunteersNCT07584720 · 32 enrolled · United States

Ahead

  1. Dec 2028Primary completion: phase 1 study in PharmacokineticsNCT03606538

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 26 Resilient Pharmaceuticals leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07584720Healthy Volunteers · United States1Active, not recruitingJul 23, 202632
NCT05173831Stress Disorders, Post-Traumatic2WithdrawnDec 20240
NCT05147402Pharmacokinetics · United States1CompletedDec 2, 202214
NCT04968938Stress Disorders, Post-Traumatic2WithdrawnAug 20230
NCT04784143Stress Disorders, Post-Traumatic · United States2TerminatedJun 25, 202426
NCT04714359Stress Disorders, Post-Traumatic · United States, Canada, Israel3CompletedNov 1, 202387
NCT04454684Binge-Eating Disorder2WithdrawnAug 10, 20280
NCT04077437Stress Disorders, Post-Traumatic · United States, Israel3CompletedOct 30, 2022121
NCT04073433Psychological Effects of Study Drug1WithdrawnDec 20250
NCT03606538Pharmacokinetics · United States1Not yet recruitingDec 202816
NCT03537014Stress Disorders, Post-Traumatic · United States, Canada, Israel3CompletedAug 11, 2020100
NCT03485287Stress Disorders, Post-Traumatic · Canada2CompletedJun 4, 20194
NCT03282123Stress Disorders, Post-Traumatic · United States2CompletedAug 10, 201938
NCT03181763Startle Response · United States1CompletedAug 1, 202034
NCT02876172Stress Disorders, Post-Traumatic · United States2CompletedDec 16, 201712
NCT02427568Anxiety Disorders · United States2CompletedApr 25, 201718
NCT02008396Autistic Disorder · United States2CompletedApr 28, 201712
NCT01958593Stress Disorders, Post-Traumatic · Canada2TerminatedSep 10, 20156
NCT01793610Stress Disorders, Post-Traumatic · United States2CompletedDec 3, 201529
NCT01689740Stress Disorders, Post-Traumatic · Israel2CompletedApr 7, 201610
NCT01458327Stress Disorders, Post-Traumatic · United States2CompletedJun 27, 20143
NCT01404754Psychological Effects of Study Drug · United States1CompletedAug 5, 2022107
NCT01211405Stress Disorders, Post-Traumatic · United States2CompletedJun 4, 201526
NCT00402298Stress Disorders, Post-Traumatic · Israel2TerminatedMar 20095
NCT00353938Stress Disorders, Post-Traumatic · Switzerland2CompletedSep 2, 200914
NCT00090064Stress Disorders, Post-Traumatic · United States2CompletedMay 2, 200823

How it is read

Names in the registry

  • “Midomafetamine HCl”, 10 entries
  • “Midomafetamine”, 7 entries
  • “midomafetamine HCl”, 2 entries
  • “MDMA”, 2 entries
  • “midomafetamine”, 2 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.